| Автор | Paltiel, A., David |
| Автор | Scharfstein, Julie, A. |
| Автор | Seage, George, R. |
| Автор | Losina, Elena |
| Автор | Goldie, Sue, J. |
| Автор | Weinstein, Milton, C. |
| Автор | Craven, Donald, E. |
| Автор | Freedberg, Kenneth, A. |
| Дата выпуска | 1998 |
| dc.description | Background. Disagreement exists among decision makers regarding the allocation of limited HIV patient care resources and, specifically, the comparative value of prevent ing opportunistic infections in late-stage disease. Methods. A Monte Carlo simulation framework was used to evaluate a state-transition model of the natural history of HIV illness in patients with CD4 counts below 300/mm<sup>3</sup> and to project the costs and con sequences of alternative strategies for preventing AIDS-related complications. The au thors describe the model and demonstrate how it may be employed to assess the cost-effectiveness of oral ganciclovir for prevention of cytomegalovirus (CMV) infec tion. Results. Ganciclovir prophylaxis confers an estimated additional 0.7 quality-ad justed month of life at a net cost of $10,700, implying an incremental cost-effective ness ratio of roughly $173,000 per quality-adjusted life year gained. Sensitivity analysis reveals that this baseline result is stable over a wide range of input data estimates, including quality of life and drug efficacy, but it is sensitive to CMV incidence and drug price assumptions. Conclusions. The Monte Carlo simulation framework offers decision makers a powerful and flexible tool for evaluating choices in the realm of chronic disease patient care. The authors have used it to assess HIV-related treatment options and continue to refine it to reflect advances in defining the pathogenesis and treatment of AIDS. Compared with alternative interventions, CMV prophylaxis does not appear to be a cost-effective use of scarce HIV clinical care funds. However, targeted pre vention in patients identified to be at higher risk for CMV-related disease may warrant consideration. Key words: Monte Carlo simulation; AIDS; HIV infection; cytomegalo virus infection; cost-effectiveness analysis. (Med Decis Making 1998;18 suppl:S93- S105) |
| Издатель | Sage Publications |
| Название | A Monte Carlo Simulation of Advanced HIV Disease |
| Тип | Journal Article |
| DOI | 10.1177/0272989X9801800211 |
| Print ISSN | 0272-989X |
| Журнал | Medical Decision Making |
| Том | 18 |
| Первая страница | S93 |
| Последняя страница | S105 |
| Выпуск | 2S |
| Библиографическая ссылка | Aboulker J., Swart A.Preliminary analysis of the Concorde trial. Lancet.1993;341:889-90. |
| Библиографическая ссылка | Carpenter Ccj , Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel . JAMA. 1996;276:146-54. |
| Библиографическая ссылка | Enger C., Graham N., Peng Y., et al. Survival from early, intermediate, and late stages of HIV infection . JAMA. 1996;275: 1329-34. |
| Библиографическая ссылка | Fischl MA, Richman DD, Grieco MH, and The AIDS Clinical Trials Group.The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med.1987 ;317:185-91. |
| Библиографическая ссылка | Fischl MA, Richman DD, Hansen N., and The AZT Collaborative Working Group.The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection . Ann Intern Med. 1990;112:727-37. |
| Библиографическая ссылка | Graham N., Zeger S., Park L., et al. The effects on survival of early treatment of HIV infection . N Engl J Med. 1992;326: 1037-42. |
| Библиографическая ссылка | Harris JEImproved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987. JAMA . 1990;263:397-401. |
| Библиографическая ссылка | Lemp GF, Payne SF, Neal D., Temelso T., Rutherford GWSurvival trends for patients with AIDS. JAMA.1990;263:402-6. |
| Библиографическая ссылка | Seage G., Oddleifson S., Carr E., et al. Survival with AIDS in Massachusetts 1979-1989. Am J Public Health.1993;83:72-8. |
| Библиографическая ссылка | Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med.1990;322:941-9. |
| Библиографическая ссылка | Hellinger FJThe lifetime cost of treating a person with HIV. JAMA.1993;270:474-8. |
| Библиографическая ссылка | Scitovsky AA , Rice DP Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. public Health Rep. 1987;102:5-17. |
| Библиографическая ссылка | Seage GR, Landers S., Barry MA, Groopman J., Lamb G., Epstein A.Medical care costs of AIDS in Massachusetts. JAMA.1986;256:3107-9. |
| Библиографическая ссылка | Arno PS, Shenson D., Siegel NF, Franks P., Lee PREconomic and policy implications of early intervention in HIV disease. JAMA.1989;262:1493-8. |
| Библиографическая ссылка | Hoover DR, Saah AJ, Bacellar H., et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis . Multicenter AIDS Cohort Study. N Engl J Med. 1993;329:1922-6. |
| Библиографическая ссылка | Centers for Disease Control and Prevention.USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR. June 27, 1997; 46(RR-12):1-46. |
| Библиографическая ссылка | National Alliance of State and Territorial AIDS Directors.The fiscal status of AIDS drug assistance programs: findings from a January 1996 national survey of state AIDS directors . Prepared for the United States Health Resources and Services Administration, Division of HIV Services, April 1996. |
| Библиографическая ссылка | McGinley L.States move to ration promising AIDS drugs . Wall Street Journal. August 22, 1996:B1. |
| Библиографическая ссылка | Pear R.Expense means many can't get drugs for AIDS. New York Times . February 16, 1997:A1. |
| Библиографическая ссылка | Schooley RTCytomegalovirus in the setting of infection with human immunodeficiency virus. Rev Infect Dis.1990;12: S811-S819. |
| Библиографическая ссылка | Hirsch MSCytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome. Transplant Proc.1991;23, suppl 3:118-21. |
| Библиографическая ссылка | Erice A., Chou S., Biron KK, Stanat SC, Balfour HH, Jordan MCProgressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med.1989; 320:289 - 93. |
| Библиографическая ссылка | Balfour HHManagement of cytomegalovirus disease with antiviral drugs. Rev Infect Dis.1990;12:S849-S860. |
| Библиографическая ссылка | Merigan TC, Resta S.Cytomegalovirus: Where have we been and where are we going? Rev Infect Dis.1990;12, suppl 7: S693-S700. |
| Библиографическая ссылка | Merigan TCTreatment of cytomegalovirus infection in the AIDS patient. Transplant Proc.1991;23, suppl 3:122-5. |
| Библиографическая ссылка | Polis MA, deSmet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). Am J Med.1993;94:175-80. |
| Библиографическая ссылка | Drug Topics Red Book. Montvale, NJ: Medical Economics, 1996. |
| Библиографическая ссылка | Spector SA, McKinley GF, Lalezari JP, et al, and the Roche Cooperative Oral Ganciclovir Study Group.Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med.1996;334:1491-7. |
| Библиографическая ссылка | Feinberg J., Cooper D., Hurwitz S., for the ACTG204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. Phase III International Study of valaciclovir (VACV) for cytomegalovirus (CMV) prophylaxis in patients with advanced HIV disease. Presentation Th.B.300, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada. |
| Библиографическая ссылка | Brosgart C., Craig C., Hillman D., et al. Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease. Presentation Th.B.301, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada. |
| Библиографическая ссылка | Robbins GK, Cotton DJCost-effectiveness of ganciclovir for prevention of CMV retinitis . Abstract 296, Session 31, 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1997. |
| Библиографическая ссылка | Rose DN, Sacks HSCost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing . AIDS. 1997;11:883-7. |
| Библиографическая ссылка | Gold MR, Siegel JR, Russell LB, Weinstein MCCost-effectiveness in Health and Medicine. Report of the Panel on Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996. |
| Библиографическая ссылка | Doubilet P. , Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making. 1985;5:157-77. |
| Библиографическая ссылка | Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R.Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Imune Defic Syndr Hum Retrovirol.1992;5:1069-74. |
| Библиографическая ссылка | Phair J., Munoz A., Detels R., Kaslow R., Rinaldo C., Saah A., and The Multicenter AIDS Cohort Study Group.The risk of Pneumocystis carinii pneumonia among men infected with HIV Type I. Multicenter AIDS Cohort Study Group. N Engl J Med.1990;322:161-5. |
| Библиографическая ссылка | Kaplan JE, Masur H., Jaffe HW, Holmes KKPreventing opportunistic infections in persons infected with HIV. 1997 guidelines . JAMA. 1997;278:337-8. |
| Библиографическая ссылка | Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JPAntiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference. JAMA.1993;270:2583-9. |
| Библиографическая ссылка | U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection.Recommendations for prophylaxis against Pnuemocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR. 1992; 41(RR-4):1-11. |
| Библиографическая ссылка | Freedberg KA , Scharfstein JA, Seage GR, et al. The cost-ef fectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279:130-6. |
| Библиографическая ссылка | Scharfstein JA , Paltiel AD, Weinstein MC, Freedberg KA The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS. Under review. |
| Библиографическая ссылка | Kaslow RA, Ostrow DG, Detels R., Phair JP, Polk BF, Rinaldo CRThe Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol.1987;126:310-8. |
| Библиографическая ссылка | Multicenter AIDS Cohort Study (MACS).Public Data Set (Release PO4). Springfield, VA : National Technical Information Service, 1995. |
| Библиографическая ссылка | Laird NM, Ware JHRandom effects model for longitudinal data. Biometrics.1982;38:963-74. |
| Библиографическая ссылка | Miller DK, Homan SMDetermining transition probabilities. Med Decis Making.1994;14:52-8. |
| Библиографическая ссылка | Hardy WD, Feinberg J., Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trial Group Protocol 021. N Engl J Med.1992;327:1842-8. |
| Библиографическая ссылка | AIDS Cost and Services Utilization Survey. Public use tapes #4 and #5. #PB94-189891, Springfield, VA: National Technical Information Service, 1994. |
| Библиографическая ссылка | Hellinger FJForecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry.1992 ;29:356-65. |
| Библиографическая ссылка | Hellinger FJ , Fleishman JA, Hsia DC AIDS treatment costs during the last months of life: evidence from the ACSUS. Health Serv Res. 1994;29:569-81. |
| Библиографическая ссылка | Finkler SAThe distinction between cost and charges. Ann Intern Med.1982;96:102-9. |
| Библиографическая ссылка | United States Bureau of the Census.Statistical Abstract of the United States: 1996. 116th ed. Washington, DC, 1996. |
| Библиографическая ссылка | Paltiel AD, Stinnett AAAIDS. In: Spilker B (ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. New York: Raven , 1996. |
| Библиографическая ссылка | Tsevat J., Solzan JG, Kuntz K., et al. Health values of patients infected with human immunodeficiency virus. Med Care.1996; 34:44-57. |
| Библиографическая ссылка | Torrance GW , Boyle MH, Horwood SP Application of multiattribute utility theory to measure social preferences for health states. Operations Research. 1982;30:1043-69. |
| Библиографическая ссылка | Stiggelbout AM, Eijkemans Mjc, Kiebert GM, et al. The "utility" of the visual analog scale in medical decision making and technology assessment . Int J Technol Assess Health Care. 1996;12:291-8. |
| Библиографическая ссылка | van Hout B. , Bonsel G., Habbema D., van der Maas P. Heart transplantation in the Netherlands; costs, effects, and scenarios. J Health Econ. 1993;12:73-93. |
| Библиографическая ссылка | de Haes Jcjm , de Koning HJ, van Oortmarssen GJ, et al. The impact of a breast cancer screening programme on quality-adjusted life-years . Int J Cancer. 1991;49:538-44. |
| Библиографическая ссылка | Torrance GWSocial preferences for health states: an empirical evaluation of three measurement techniques. Socioeconomic Planning Science.1976;10:128-36. |
| Библиографическая ссылка | Microsoft Visual C++, Version 2.0 (1995). Microsoft Windows 95, Version 4.00.950 (1996). |
| Библиографическая ссылка | Weinstein MC , Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model. Am J Public Health. 1987;77:1417-26. |
| Библиографическая ссылка | Eddy DM, Hasselblad V., McGivney W., Hendee W.The value of mammography screening in women under age 50 years. JAMA.1988;259:1512. |
| Библиографическая ссылка | Jager J, Ruitenberg E (eds). AIDS Impact Assessment: Modeling and Scenario Analysis. Amsterdam, The Netherlands: Elsevier, 1992. |
| Библиографическая ссылка | Pliskin JS, Tell EJA dialysis need forecasting model: a retrospective evaluation. Med Decis Making.1983;3:489-500. |
| Библиографическая ссылка | Keeler E.Decision trees and Markov models in cost-effectiveness research. In: Sloan FA (ed). Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies . New York: Cambridge University Press, 1995. |
| Библиографическая ссылка | Beck JR, Pauker SGThe Markov process in medical prognosis. Med Decis Making.1983;3:419-58. |
| Библиографическая ссылка | Holtgrave DR , Qualls NL Threshold analysis and programs for prevention of HIV infection. Med Decis Making. 1995;15: 311-7. |
| Библиографическая ссылка | Kaplan RM, Bush JWHealth-related quality of life measurement for evaluation research and policy analysis. Health Psychol.1981;1:61-80. |
| Библиографическая ссылка | Owens DK, Nease RF, Harris RAUse of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings (abstr). Med Decis Making.1993;13:395. |
| Библиографическая ссылка | Drummond MF , Torrance GW, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med. 1993;37: 33-40. |
| Библиографическая ссылка | Mason J., Drummond MF, Torrance GWSome guidelines on the use of cost-effectiveness league tables. BMJ.1993;306: 570-2. |
| Библиографическая ссылка | Weinstein MCFrom cost-effectiveness ratios to resource allocation: where to draw the line ? In: Sloan FA (ed). Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies. New York: Cambridge University Press, 1995. |
| Библиографическая ссылка | Freedberg KA , Tosteson Ana, Cohen CJ, Cotton DJ Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected persons with CD4 counts below 200/mm3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr Hum Virol. 1991;4:521-31. |
| Библиографическая ссылка | Castellano AR, Nettleman MDCost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA.1991;266:820-4. |
| Библиографическая ссылка | Freedberg KA , Cohen CJ, Barber TW Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:275-82. |
| Библиографическая ссылка | McCarthy B. , Wong J., Munoz A., Sonnenberg F. Who should be screened for HIV infection? Arch Intern Med. 1993;153: 1107-16. |
| Библиографическая ссылка | Owens DK, Nease RF, Harris RACost-effectiveness of HIV screening in acute care settings. Arch Intern Med.1996;156: 394-404. |
| Библиографическая ссылка | Moore RD, Bartlett JGCombination antiviral therapy in HIV infection: an economic perspective . PharmacoEconomics. 1996;10:109-13. |
| Библиографическая ссылка | Spector SA, Pilcher M., Lamy P., Hsia K., Wong R., Stempien MJ, and the Roche Cooperative Oral Ganciclovir Study Group.PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis. Presentation Th.B.302, 11th International Conference on AIDS, 1996, Vancouver, BC, Canada. |
